In the BioHarmony Drug Report Database

"Preview" Icon

Panobinostat

Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 4, histone deacetylase 1, histone deacetylase 9, histone deacetylase 2, histone deacetylase 8, histone deacetylase 6, histone deacetylase 7, and histone deacetylase 3. Farydak’s patents are valid until 2028-06-13 (FDA).

 

Trade Name

 

Farydak
 

Common Name

 

panobinostat
 

ChEMBL ID

 

CHEMBL483254
 

Indication

 

multiple myeloma
 

Drug Class

 

Enzyme inhibitors: inhibitors of histone deacetylase

Image (chem structure or protein)

Panobinostat structure rendering